The fluorinated analog of deoxycytidine, Gemcitabine (Gemzar), is the main chemotherapeutic drug in pancreatic cancer, but survival remains weak mainly because of the high resistance of tumors to the drug. Recent works have shown that the mucin MUC4 may confer an advantage to pancreatic tumor cells by modifying their susceptibility to drugs. However, the cellular mechanism(s) responsible for this MUC4-mediated resistance is unknown. The aim of this work was to identify the cellular mechanisms responsible for gemcitabine resistance linked to MUC4 expression. CAPAN-2 and CAPAN-1 adenocarcinomatous pancreatic cancer (PC) cell lines were used to establish stable MUC4-deficient clones (MUC4-KD) by shRNA interference. Measurement of the IC 50 index using tetrazolium salt test indicated that MUC4-deficient cells were more sensitive to gemcitabine. This was correlated with increased Bax/Bcl XL ratio and apoptotic cell number. Expression of Equilibrative/Concentrative Nucleoside Transporter (hENT1, hCNT1/3), deoxycytidine kinase (dCK), ribonucleotide reductase (RRM1/2) and Multidrug-Resistance Protein (MRP3/4/5) was evaluated by quantitative RT-PCR (qRT-PCR) and western blotting. Alteration of MRP3, MRP4, hCNT1 and hCNT3 expression was observed in MUC4-KD cells, but only hCNT1 alteration was correlated to MUC4 expression and sensitivity to gemcitabine. Decreased activation of MAPK, JNK and NF-kB pathways was observed in MUC4-deficient cells, in which the NF-kB pathway was found to have an important role in both sensitivity to gemcitabine and hCNT1 regulation. Finally, and in accordance with our in vitro data, we found that MUC4 expression was conversely correlated to that of hCNT1 in tissues from patients with pancreatic adenocarcinoma. This work describes a new mechanism of PC cell resistance to gemcitabine, in which the MUC4 mucin negatively regulates the hCNT1 transporter expression via the NF-kB pathway. Altogether, these data point out to MUC4 and hCNT1 as potential targets to ameliorate the response of pancreatic tumors to gemcitabine treatment.
INTRODUCTION
Pancreatic adenocarcinoma is one of the most deadly cancers in western countries with an extremely poor prognosis (survival rate of 6 months). 1 This marked outcome is related to a lack of efficient therapeutic tools and early diagnostic markers. At the time of diagnosis, more than 80% of patients have metastasis or locally advanced cancer. Only about 10 to 15% of patients are considered eligible for surgical resection. Gemcitabine (Gemzar), a fluorinated analog of deoxycytidine, is the main chemotherapeutic drug used in firstline in advanced pancreatic cancer (PC). Despite the improvement of quality of life of patients, the gain in survival remains short (6 additional months). This is mainly due to the high resistance of pancreatic tumor cells to the drug. 2, 3 Deciphering mechanisms responsible for PC cell resistance to gemcitabine is thus mandatory if one wants to improve efficacy of the drug and propose more efficient therapies.
One way to explain modifications of cell sensitivity to gemcitabine is an alteration of the factors responsible for its metabolism and more particularly nucleoside transporters. Gemcitabine is taken up by the cell mainly by human Equilibrative Nucleoside Transporter 1 (hENT1) and by human Concentrative Nucleoside Transporter 1 and 3 (hCNT1 and hCNT3). 4 It has been shown that the expression of hENT1 and hCNT3 in pancreatic tumors is correlated with chemosensitivity and overall survival, making them good predictive markers for patient survival. [5] [6] [7] Moreover, hCNT1 was shown to be frequently decreased in pancreatic tumors and, in most of the PC cell lines, this decrease being correlated with gemcitabine cytotoxicity, suggesting the importance of hCNT1 in improving the sensitivity to gemcitabine. 8, 9 On the basis of expression and molecular studies, mucins, especially the MUC4 mucin, have been proposed as factors of chemoresistance. [10] [11] [12] MUC4 is a membrane-bound mucin, which is not expressed in healthy pancreas but is expressed in the very early steps of pancreatic carcinogenesis. 13 MUC4 involvement in biological properties of PC cells is well described. [14] [15] [16] [17] [18] However, the mechanisms linking MUC4 expression to gemcitabine sensitivity of PC cells remain to be determined.
The aim of this work was to decipher the molecular mechanisms linking MUC4 expression and gemcitabine resistance of PC cells. For that, we hypothesized that MUC4 could alter expression of factors of gemcitabine metabolism and/or detoxifying channels.
We show in this paper that the loss of MUC4 in PC cells induces sensitivity to gemcitabine and involves MUC4 regulation of hCNT1 expression via the NF-kB pathway.
RESULTS

MUC4-deficient cells are more sensitive to gemcitabine
Sensitivity of MUC4-deficient cells (MUC4-KD) to gemcitabine was studied in CAPAN-2 and CAPAN-1 PC cells. Measurement of IC 50 shows that the loss of MUC4 leads to an increased sensitivity of CAPAN-2 (MUC4-KD ¼ 34.8 ± 1.8 nM vs Mock ¼ 52.9 ± 2.2 nM) ( Figure 1a ) and CAPAN-1 (MUC4-KD ¼ 80 ± 2 nM vs Mock ¼ 145±15 nM) (Supplementary Figure 1A) cells to gemcitabine. A similar effect was observed at a longer time point (6 days) in both CAPAN-1 and CAPAN-2 cells (data not shown). Sensitivity of MUC4-KD cells to another cytidine analog, the cytarabine/aracytin ARA-C, was also evaluated after 72 h of treatment. Interestingly, we also observed an increased sensitivity of MUC4-KD cells (IC 50 ¼ 1.3 mM ± 0.3) when compared with Mock cells (3.2 mM ± 0.6). Cell sensitivity to the alkylating agent oxaliplatin, on the other hand, was not affected by the lack of MUC4 (MUC4-KD ¼ 1.35 ± 0.06 mM vs Mock ¼ 1.15 ± 0.05 mM) (data not shown). The increase of gemcitabine-induced cytotoxicity in MUC4-KD cells was accompanied by an increased expression of the proapoptotic marker Bax and a decreased expression of the antiapoptotic marker Bcl XL , leading to an increase of the Bax/Bcl XL ratio, suggesting a higher susceptibility to apoptosis in both cell lines ( Figure 1b and Supplementary Figure 1A) . Moreover, the activation of the apoptotic mediator p53 was increased in MUC4-KD cells (Figure 1b) . To confirm these observations, the apoptotic index was determined after gemcitabine treatment by annexin-V staining followed by cytometry analysis. MUC4-KD clones, as expected, have a statistically significant higher apoptotic index than Mock cells (P ¼ 0.0025) (Figure 1c) . Altogether, these results indicate that MUC4 involvement in gemcitabine sensitivity implies alteration of the apoptotic balance in PC cells.
Alteration of gemcitabine metabolism marker expression in MUC4-KD cells Gemcitabine efficiency depends on the state of nucleoside metabolism for its activation and incorporation into DNA. Modification of nucleoside transporters (hENT1, hCNT1 and 3) or deoxycytidine kinase (dCK) 19, 20 expression contributes to gemcitabine efficiency. On the contrary, multidrug resistanceassociated protein family (MRP) channels 21 and ribonucleotide reductase (RRM1 and 2) 22 contribute to maintaining a drugresistant phenotype. As shown in Figure 2a , CAPAN-2 MUC4-KD cells strongly overexpressed mRNA of MRP3 channel (ninefold), hCNT1 (sevenfold) and hCNT3 (twofold) transporters compared with Mock cells, whereas MRP4 channel mRNA expression was decreased (twofold). Increased expression of hCNT1, hCNT3 and MRP3, and decreased expression of MRP4, was confirmed at the protein level by western blotting (Figure 2b ). Implication of these four markers in cell sensitivity to the drug was then tested by transient siRNA approach (Supplemental Figure 2A) . Decreased expression of MRP3 did not alter cytotoxicity to gemcitabine (Figure 2c ), whereas hCNT1, hCNT3 and MRP4 repression led to a statistically significant (Po0.0001, P ¼ 0.0372, P ¼ 0.0007, respectively) increase in survival (Figure 2c ). These results suggest an implication of hCNT1, hCNT3 and MRP4 in gemcitabine sensitivity, with hCNT1 and hCNT3 effect correlated to both MUC4 expression and MUC4-KD cell sensitivity. In CAPAN-1 MUC4-KD cells, increased expression of hCNT1 was also found, whereas hCNT3 expression remained the same when compared with Mock cells (Supplementary Figure 1B) . Therefore, in the rest of the paper, we focused our studies on hCNT1 transporter, for which biological effects were correlated to MUC4 expression in the two cell lines. All experiments were performed three times independently.
MAPK, JNK and NF-kB pathways are altered in MUC4-KD cells and modulate sensitivity to gemcitabine To understand the molecular mechanisms that regulate hCNT1 expression, we first studied alteration of the main signaling pathways in MUC4-KD cells. We show that the loss of MUC4 in both CAPAN-2 and CAPAN-1 cells induces a decrease of both Erk1/ 2 and JNK activation, and a decrease of NF-kB p65 expression ( Figure 3a and Supplementary Figure 3A) . The translocation to the nucleus of NF-kB p50 and p65 subunits was also decreased in MUC4-KD cells, as the nuclear amount of the two subunits was diminished in MUC4-KD cells compared with Mock cells (Figure 3b ). This was correlated with a decreased activity of the kB-Luc synthetic promoter ( Figure 3c and Supplementary Figure 3B ). Moreover, pharmacological inhibition of the MAPK (U0126) and JNK (SP600125) pathways induced a strong decrease of NF-kB expression ( Figure 3d ) and promoter activity (Figure 3e ), suggesting a link between these pathways. Implication of these three pathways in gemcitabine sensitivity was then investigated using specific siRNAs to target Erk1/2 and JNK kinases, and NF-kB p105 (precursor of NF-kB p50 subunit) (Supplementary Figure 2B) . The results indicate that decreased NF-kB expression leads to increased sensitivity to gemcitabine (Figure 4a ), correlated to an increased Bax/Bcl XL ratio (Figure 4b ). On the contrary, decreased Erk1/2 and JNK expression led to a decreased sensitivity to gemcitabine (Figure 4a ), correlated to a decreased Bax/Bcl XL ratio (Figure 4b ). These results suggest that targeting the NF-kB pathway appears to be more appropriate if one wants to alter the cell sensitivity to gemcitabine.
The NF-kB pathway regulates hCNT1 expression The hCNT1 mRNA expression was measured by qRT-PCR after CAPAN-2 cell treatment with specific pharmacological inhibitors of MAPK (U0126), JNK (SP600125) and NF-kB (BAY-11-7082) pathways ( Figure 5a ). The results indicate that inhibition of MAPK leads to decreased hCNT1 mRNA expression (twofold), whereas treatment with NF-kB inhibitor induced increase of hCNT1 mRNA level (1.5-fold). No modification of hCNT1 mRNA level was observed following treatment with JNK pathway inhibitor. To confirm the implication of the NF-kB pathway on hCNT1 regulation, the inhibitor of kappa B (IkB) was overexpressed in both CAPAN-2 and CAPAN-1 cells and hCNT1 mRNA level was measured ( Figure 5b and Supplementary Figure 3C ). Decreased activity of NF-kB using the synthetic kB-Luc promoter confirmed the efficiency of IkB. Similar to pharmacological inhibition, overexpression of IkB increased hCNT1 mRNA expression ( Figure 5b ). Increased hCNT1 expression at the protein level was then confirmed after either IkB overexpression or transfection of NF-kB p105 siRNA ( Figure 5c ). Taken together, these results clearly show that the NF-kB pathway negatively regulates hCNT1 expression.
MUC4 expression is conversely correlated to hCNT1 in tissues from patients with pancreatic adenocarcinoma Having shown in vitro that MUC4 expression is correlated with a decreased expression of hCNT1 in PC cells, we undertook to study their expression on a small population of tissues from 16 patients with pancreatic adenocarcinoma. Immunohistochemical stainings show that MUC4 was expressed in 10/16 PC samples and hCNT1 expressed in 9/16 PC tumors (Figure 6a ). In MUC4-positive tumors, 7/10 patients did not express hCNT1. Interestingly, 100% of the samples not expressing MUC4 were positive for hCNT1 (6/6), suggesting a converse expression of MUC4 and hCNT1. Moreover, Fisher's exact test indicated that proportions differed significantly (P ¼ 0.0114) (Figure 6b ). 
DISCUSSION
A major and marked characteristic of pancreatic adenocarcinoma is the high resistance to chemotherapy leading to low efficiency of therapies, in particular those based on gemcitabine. The understanding of mechanisms underlying chemoresistance is thus mandatory if one wants to identify new predictive and/or prognostic markers and develop new therapeutic approaches. In this study, we show that the MUC4 mucin is involved in PC cell chemoresistance to gemcitabine via two complementary mechanisms involving apoptosis repression for one and nucleoside transporter hCNT1 inhibition via the NF-kB pathway for the other. Neo-expression of MUC4 in the early steps of pancreatic carcinogenesis suggests that this membrane-bound mucin is implicated in the acquisition of an aggressive phenotype by tumors 23 and as such has been proposed as a new biomarker. Several in vitro and in vivo studies have shown that MUC4 modulates tumor growth, invasion, adherence and apoptosis. 14, [16] [17] [18] Very recently, we have also shown that the PC cells lacking MUC4 were less proliferative with decreased cyclin D1 expression and G1 cell cycle arrest. 15 Altogether, these alterations could potentially confer chemoresistance capacity to tumor cells.
On the basis of these observations, Bafna et al. 10 have shown that MUC4 expression in CD18/HPAF PC cell line decreases Bad pro-apoptotic activity by its phosphorylation via Erk1/2 kinase, thereby decreasing gemcitabine cytotoxicity. In this report, we show that the loss of MUC4 is sufficient to modify Bax (pro-apoptotic) and Bcl XL (anti-apoptotic) expression, leading to an increase of Bax/Bcl XL ratio, indicating an increase in susceptibility to apoptosis. The importance of the Bax/Bcl XL ratio is attested by the fact that it is associated in prostate, 24 breast 25 and pancreatic cancers 26 with chemotherapeutic sensitivity and has been proposed as a predictive marker. In our cellular models, the regulation of Bax and Bcl XL by MUC4 seems in part to be mediated by the NF-kB pathway, and not by Erk1/2 and JNK pathways ( Figure 7) . Our results are thus in favor of a role for MUC4 as an apoptosis regulator that would influence PC cell resistance to gemcitabine.
However, gemcitabine cytotoxic effect cannot be optimal in the absence of an efficient metabolism pathway to take up the drug. This is especially true for resistant tumor cells that often exhibit an altered metabolism of gemcitabine. In this study, the absence of MUC4 in PC cells led to a marked modification in hCNT1 and hCNT3 transporters, as well as MRP3 and MRP4 drug-detoxifying channels expression levels. We also show that hCNT1, hCNT3 and MRP4 are involved in gemcitabine sensitivity. MRP channels are able to export out of the cell a wide range of lipophilic anions such as chemotherapeutic drugs to maintain a drug-resistant phenotype. Overexpression of MRP3 was found in several cancers, such as ovarian, 27 lung 28 and pancreatic cancers. 29 MRP3 overexpression was correlated to cell chemoresistance to several drugs, such as methotrexate, etoposide, doxorubicin and platinum agents. Nevertheless, in these studies MRP3 was not implicated in nucleoside-derived drug resistance. In our work, MRP3 was also not an actor of drug resistance as opposed to MRP4. Similar to MRP5 and MRP8, MRP4 is able to transport cyclic nucleotides out of the cell and was previously shown to confer cell chemoresistance to 6-mercaptopurine and 6-thioguanine in leukemia, 30 as well as to methotrexate. 31 Although the implication of MRP5 in 5-fluorouracil and gemcitabine resistance was demonstrated, 32 the role of MRP4 remains unclear. In this work, we show that MRP4 expression is conversely correlated to gemcitabine resistance, making this channel a potential interesting marker that is independent of MUC4 expression (Figure 7) . A similar result has been previously described in which resistance to several drugs in melanoma cells by Muc4 expression was conversely correlated to MDR1 and MRP1, which are members of multidrug resistance family. 33 We thus propose that MRP4 acts independently of MUC4 to convey gemcitabine sensitivity.
Interestingly, hCNT1 is upregulated when MUC4 is inhibited, and this is correlated to drug sensitivity. The same result was found for hCNT3. This correlation was observed in both CAPAN-1 and CAPAN-2 cells for hCNT1, but only in CAPAN-2 for hCNT3. This suggests a cell-specific mechanism for hCNT3. Although in vitro studies have correlated hCNT1 expression with a drug-resistant phenotype of PC cells, 8, 9 no significant evidence has proven in vivo implication with a correlation to a better patient outcome. Our in vitro and ex vivo data indicate that MUC4 and hCNT1 expression are conversely correlated in PC cells, as well as in tumor samples from patients with pancreatic adenocarcinoma. These data confer to MUC4 a potential as a predictive marker and will have to be confirmed in bigger cohorts.
Investigation of hCNT1 regulation by MUC4 led us to show that the NF-kB pathway mediates this mechanism. The NF-kB pathway is well known to be constitutively activated in PC compared with normal pancreas. 34 NF-kB also promotes tumor progression by regulating genes implicated in proliferation, angiogenesis and survival. Implication of the NF-kB pathway in chemoresistance to gemcitabine was already described and was found to modulate apoptosis. 35 In our work, in addition to apoptotic regulation, we highlight a new resistance mechanism mediated by the NF-kB pathway that leads to the downregulation of hCNT1 thereby decreasing gemcitabine uptake and efficiency ( Figure 7) . Our results support the promising current effort to improve gemcitabine efficacy by targeting the NF-kB pathway with natural 36, 37 or chemical 38 inhibitors or by siRNA delivery. 39 We have described in this paper two complementary resistance mechanisms of PC cells to gemcitabine that are linked to MUC4. They are mediated by the NF-kB pathway and lead to (i) the modulation of apoptosis and (ii) the regulation of hCNT1 transporter expression. These data reinforce the value of MUC4 as a prognostic marker. Interestingly, cell sensitivity to cytarabine/ aracytin (ARA-C), another cytidine analog, mainly used in leukemia or lymphoma, but that is incorporated into human DNA via a similar metabolic pathway as in gemcitabine, was also altered in MUC4-KD cells. This suggests that our findings regarding the role of MUC4 in drug resistance could be extended to other nucleoside analogs and other types of cancer. FOLFIRINOX, a new therapeutic protocol, which combines therapeutic agents (5-fluorouracil, irinotecan, oxaliplatin and leucovorin), brings hope as statistical and clinical significant benefit compared with gemcitabine alone was reported in patients with advanced pancreatic cancer. 40 Interestingly, 5-fluorouracil was shown to induce MRP3 expression increasing oxaliplatin efficiency, 41 whereas MRP4 expression increases irinotecan resistance. 42 In preliminary experiments, we have also found that the loss of MUC4 leads to an increased sensitivity of CAPAN-2 cells to 5-fluorouracil (personal communication). Taking into account these recent data and ours, targeting MUC4 would certainly improve efficiency of the FOLFIRINOX protocol and is at this time under investigation.
MATERIALS AND METHODS
Cell culture
CAPAN-1 and CAPAN-2 PC cell lines were cultured as described previously .
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MUC4 knocked-down (MUC4-KD) cells were obtained by stable transfection with pRetroSuper plasmid (SA Biosciences, Qiagen, Courtaboeuf, France) containing a small-hairpin RNA targeting MUC4 (5 0 -AAGTGG AACGAATCGATTCTGTTCAAGAGACAGAATCGATTCGTTCCACTT-3 0 ). Control cells (Mock) were obtained by transfecting the empty-vector pRetroSuper plasmid. After selection with neomycine (300 mg/ml) and serial limit dilution, expression of MUC4 was controlled by western blotting. Four selected clones of Mock and MUC4-KD cells were pooled in order to avoid clonal variation. All cells were maintained in a 37 1C incubator with 5% CO 2 and cultured as the parental cells. Pharmacological inhibitors were added to the cells and incubated for 24 h at the following final concentrations: U0126 (10 mM, inhibitor of MAPK, Calbiochem, Merck Chemical Limited, Nottingham, UK), SP600125 (10 mM, inhibitor of JNK, Calbiochem) and BAY-11-7082 (10 mM, inhibitor of NF-kB, Calbiochem).
Protein extraction
Cytosolic, nuclear and total cellular extracts were performed as previously described in Van Seuningen et al. 44 and Jonckheere et al., 45 respectively.
Western blotting
Western blotting on nitrocellulose membrane (0.2 mm, Whatman) was carried out as described previously. 46 Membranes were incubated with antibodies against phospho-Erk1/2 (Thr202/Tyr204) (clone 20G11, 1/500), Erk1/2 (clone I37F5, 1/500), NF-kB Phospho-p65 (Ser536) (clone 93H1, 1/500), NF-kB p65 (clone E498, 1/500), phospho-SAPK/JNK (Thr183/Tyr185) (9251, dilution 1/500), SAPK/JNK (clone 56G8, 1/500), phospho-p53 (Ser 15) (9284, dilution 1/500) and p53 (9282, 1/500), from Cell Signaling Peroxidase-conjugated secondary antibodies (Sigma-Aldrich) were used and immunoreactive bands were visualized using the West Pico chemoluminescent substrate (Thermo Scientific, Pierce, Brebiè res, France). Chemo-luminescence was visualized using the LAS4000 apparatus (Fujifilm, Courbevoie, France). Densities of bands were integrated using the Gel analyst software (Claravision, Paris, France) and represented as histograms. Three independent experiments were performed.
Cytotoxicity assay
Cells were seeded in growth medium into 96-well plates at a density of 10 MUC4-independent mechanisms. MRP4 channel increases cell sensitivity to gemcitabine by an unknown mechanism, whereas MRP3 is not involved. MRP5 is known to decrease cell sensitivity to gemcitabine, as well as modification of deoxycytidine kinase (dCK) and ribonucleotide reductase (RRM1 and 2). 20, 22, 32 Gemcitabine resistance linked to MUC4 expression N Skrypek et al concentration (range: 10 nM-20 mM) and incubated for 72 h at 37 1C. 
RNA interference
Transient inhibition of MRP3, MRP4, hCNT1 and hCNT3 was performed using a pool of siRNA designed by Santa Cruz Biotechnology with Effectene (Qiagen) following the manufacturer's instruction. Transient KD for Erk1 (MAPK1), Erk2 (MAPK3), JNK1 (MAPK8), JNK2 (MAPK9) and NF-kB (p105 NF-kB) was performed using siRNA from Dharmacon (Thermo Scientific) following the protocol described previously. 46 Controls were performed using a non-targeting siRNA (NT) in both protocols. Cells were seeded at a density of 5 Â 10 5 cells per well into 6-well plates for RNA and protein extraction, or at a density of 10 4 cells per well into 96-well plates for cytotoxic assay, and left for 48 h at 37 1C before gemcitabine treatment (100 nM) for another 24 h at 37 1C.
Luciferase activity
Transfection of kB-Luc synthetic promoter containing three kB-binding sites was performed with Effectene (Qiagen). Total cell extracts were prepared after 48 h incubation at 37 1C using 1x Reagent Lysis Buffer (Promega, Charbonniè res-les-Bains, France). Luciferase activity in the extracts (20 ml) was measured on a Mithras Microplate Reader LB 940 (Berthold Technologies, Thoiry, France). Total protein content in the extract (4 ml) was measured using the bicinchoninic acid method in 96-well plates (Pierce, Thermoscientific). Relative luciferase activity was expressed as fold activation of the kB-Luc vector compared with that of the empty vector pGL3 basic (Promega). In co-transfection studies, pCR3-IkB or pCR3 empty vector was transfected with kB-Luc vector. Each experiment was assayed in triplicate in at least three independent experiments.
qRT-PCR Total RNA from PC cells was prepared using the NucleoSpin RNA II kit (Macherey Nagel, Hoerdt, Germany). cDNA was prepared as described previously. 47 PCR was performed using the SsoFast Evagreen Supermix kit following the manufacturer's protocol using the CFX96 real-time PCR system (Bio-Rad). Primer information is given in Table 1 . Each marker was assayed in triplicate in three independent experiments. Expression levels of genes of interest were normalized to the mRNA level of GAPDH housekeeping gene.
Flow cytometry
Cells were plated into 6-well plates at a density of 1.5 Â 10 5 cells per well and incubated for 24 h at 37 1C before gemcitabine treatment for another 72 h. Apoptosis was measured by Annexin V-PE (Sigma-Aldrich). Briefly, cells were harvested by trypsinization, washed twice with 1 Â phosphatebuffered saline and 1 Â 10 5 cells of each condition were incubated with 5 ml of annexin V-PE (50 mg/ml) and 10 ml propidium iodide (100 mg/ml) for 10 min at room temperature. Staining intensity was determined with Cell Lab QuantaSC MPL (Beckman Coulter, Roissy, France) and analyzed with Quanta-Collection.
Immunohistochemical analyses
Pancreatic adenocarcinoma samples were obtained from 16 patients of the Lille University Hospital. No patient received either chemotherapy or Abbreviations: M, moderately differentiated; NS, not specified; P, poorly-differentiated; W, well-differentiated.
Gemcitabine resistance linked to MUC4 expression N Skrypek et al radiotherapy before the surgical resection. A consent form was obtained from each patient, and permission for removal of surgical samples was obtained from the institutional review board. Patient characteristics are given in Table 2 . Samples were processed for paraffin embedding. Tissue sections (4 mM) were stained with hematoxylin and eosin. Manual hCNT1 immunohistochemistry (IHC) was carried out as described in Van der Sluis et al. 48 and automatic MUC4 IHC with an automated immunostainer (ES, Ventana Medical System, Strasbourg, France) as in Mariette et al. 49 hCNT1 (H-70, 1/100) and MUC4 (8G7, 1/100) antibodies were purchased from Santa Cruz Biotechnology. Sections were counterstained with hematoxylin, dehydrated and mounted. A positive control for MUC4 and hCNT1 immunostainings and a negative control in the absence of primary antibody were included in each set of experiments.
Statistical analyses
Statistical analyses were performed using the Graphpad Prism 4.0 software (Graphpad softwares Inc., La Jolla, CA, USA). Differences in data of two samples were analyzed by Student's t-test or ANOVA test with selected comparison using Tukey's post-hoc test, and were considered significant for the following P-values: *Po0.05, **Po0.01 or ***Po0.001. IHC results were compared using Fisher's exact test.
